149490-61-9

Usage

Chemical Properties

Pale Beige Solid

Uses

Tirofiban intermediate.

InChI:InChI=1/C22H30N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-14,21,24H,2-6,15-17H2,1H3,(H,25,26)/t21-/m0/s1

Upstream product

• 108-89-4 picoline 
• 5264-15-3 4-(4-pyridinyl)butan-1-ol 
• 100-43-6 4-vinylpyridine 
• 102878-73-9 γ-(pyridin-4-yl)butyric acid 
• 5264-17-5 4-(pyridin-4-yl)-1-chlorobutane 
• 149463-65-0 4-(4-pyridinyl)butyl chloride hydrochloride 
• 949-67-7 L-tyrosine ethyl ester 
• 1352839-95-2 N-n-butylsulfonyl-L-tyrosine ethyl ester 

Downstream Products

• 144494-65-5 tirofiban 
• 144494-65-5 tirofiban hydrochloride 

Relevant academic research and scientific papers

Synthesis method of tirofiban hydrochloride intermediate III (by machine translation)

The invention belongs to the field, of medicine synthesis, and particularly relates to a synthesis method III of tirofiban hydrochloride intermediate. by, reduction of an intermediate I under the action of a sodium borohydride reducing system to obtain intermediate II, intermediate II under Lewis acid chloride in the presence. SOCl2 Reaction conditions of, process are mild III, and N - process operation is simple, the reaction conditions of the reaction yield, product are improved, the product purity is high, and the reaction yield is increased by, times without being subjected to column purification, to improve the clinical medication safety, of the injection using, the standard crude drug product of the pharmacopoeia standard, and is suitable, for industrial production. (by machine translation)

Tirofiban hydrochloride intermediate and preparation method of tirofiban hydrochloride

The invention provides a tirofiban hydrochloride intermediate and a preparation method of tirofiban hydrochloride. The content of isomers of the tirofiban hydrochloride intermediate and tirofiban hydrochloride prepared by the method is not higher than 0.5%, preferably not higher than 0.3%, and more preferably not higher than 0.1%; all indexes of the prepared pharmaceutical composition meet the medicinal requirements, the quality is stable in the placing process, and the clinical curative effect and the medication safety can be guaranteed.

Tirofiban hydrochloride process for preparing

The invention belongs to the field of medicine and chemical industry. According to the present invention, the tirofiban hydrochloride prepared through substitution, condensation, reduction, salification and other reactions has characteristics of high yield, good quality and good stability, and the preparation process of the present invention provides a synthesis process suitable for the practical industrial mass production.

A practical synthesis of fibrinogen receptor antagonist MK-383. Selective functionalization of (S)-tyrosine

A practical 4-step synthesis of fibrinogen receptor antagonist MK-383, N-(n-butanesulfonyl)-O-4-(4-piperidinyl)-butyl)-(S)-tyrosine, is accomplished in 48% overall yield from (S)-tyrosine. Highlights include: (1) the dual use of 4-picoline as a masked form of piperidine, and as a nucleophile precursor for a 3-carbon homologation with 3-bromo-1-chloropropane; (2) the use of trimethylsilyl groups for temporary protection of phenolic and carboxylate oxygens of (S)-tyrosine that enable selective N-sulfonylation to be carried out in high yield; (3) the selective phenolic O-alkylation of the tyrosine derivative in high yield with no racemization using aqueous KOH/DMSO; and (4) the selective hydrogenation of the pyridine ring in the presence of the tyrosine ring using Pd/C in acetic acid.